Document Detail


Vascular and cardiac effects of DV-7028, a selective, 5-HT2-receptor antagonist in rats.
MedLine Citation:
PMID:  9700989     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effect of 5HT2A-receptor antagonist DV-7028 (3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-6,7,8,9-tetrahydro - 2H-pyrido[1,2,-a]-1,3,5-triazine-2,4(3H)-dione maleate on the rat cardiovascular system was evaluated. DV-7028 (0.1 and 1.0 mg/kg), given intravenously, caused a significant, dose-dependent decrease in mean arterial blood pressure in anesthetized normotensive rats. In vagotomized rats, administration of DV-7028 resulted in a reduction of mean blood pressure, but this effect was less prominent than that seen in nonvagotomized rats. Intravenous administration of DV-7028 induced bradycardia, which was almost completely abolished by vagotomy. In pithed rats, bradycardia and hypotension were not demonstrated after DV-7028 administration. In pithed rats, serotonin administered intravenously caused a dose-dependent increase in blood pressure. In this experimental model, DV-7028 inhibited the pressor effects of serotonin at doses of 0.01 and 0.1 mg/kg, which caused neither hypotension nor bradycardia in anesthetized rats. DV-7028 strongly inhibited the pressor effects of serotonin in the isolated perfused hindlegs of the rat (IC50 = 0.032 +/- 0.004 microM) and caused a concentration-dependent, almost parallel shift to the right of the concentration-response curve to serotonin for its pressor effect in the rat perfused tail artery (pA2 value for DV-7028 was 7.92, a slope 0.94). These data demonstrate that DV-7028 exhibits 5-HT2A-receptor antagonistic property in the rat cardiovascular system. Besides this peripheral action, DV-7028, when applied in high doses, exerts hypotension and bradycardia via an unknown site and mechanism.
Authors:
D Pawlak; M Adamkiewicz; J Malyszko; A Takada; M Mysliwiec; W Buczko
Related Documents :
480149 - Sequential first-pass elimination of a metabolite derived from a precursor.
433519 - Liver cirrhosis and oestrogen metabolism--perfusion studies with cirrhotic rat livers.
17038909 - Curcumin has potent liver preservation properties in an isolated perfusion model.
8472619 - The inhibitory action of buformin, a biguanide on gluconeogenesis from alanine and its ...
4028189 - Dense line in cisterna of rough-surfaced endoplasmic reticulum of hepatocytes of the ra...
6283059 - Effects of mk-196 and furosemide on rat medullary thick ascending limbs of henle in vitro.
16236449 - Increased oxidative-related mechanisms in the spinal cord injury in old rats.
21820769 - Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (faah) inhibitors: steric e...
9417039 - Liver microsomal glucose-6-phosphatase is competitively inhibited by the lipid products...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  32     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1998 Aug 
Date Detail:
Created Date:  1998-10-14     Completed Date:  1998-10-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  266-73     Citation Subset:  IM    
Affiliation:
Department of Pharmacodynamics, University School of Medicine, Bialastrokystok, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Baroreflex / drug effects
Blood Pressure / drug effects
Cardiovascular System / drug effects*
Coronary Circulation / drug effects
Heart / drug effects*
Heart Rate / drug effects
Hindlimb / drug effects,  physiology
Injections, Intravenous
Ketanserin / pharmacology
Male
Piperidines / pharmacology*
Rats
Rats, Wistar
Receptor, Serotonin, 5-HT2A
Receptors, Serotonin / drug effects*
Ritanserin / pharmacology
Serotonin Antagonists / pharmacology*
Triazines / pharmacology*
Vagotomy
Chemical
Reg. No./Substance:
0/Piperidines; 0/Receptor, Serotonin, 5-HT2A; 0/Receptors, Serotonin; 0/Serotonin Antagonists; 0/Triazines; 133364-63-3/DV 7028; 74050-98-9/Ketanserin; 87051-43-2/Ritanserin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in h...
Next Document:  Differential effects of d-sotalol on subendocardial Purkinje myocytes isolated from normal or 10 to ...